Biophytis S.A. Issues Press Release
| Field | Detail |
|---|---|
| Company | Biophytis SA |
| Form Type | 6-K |
| Filed Date | Aug 28, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: press-release, filing-update
TL;DR
Biophytis dropped a press release on 8/28, details TBD.
AI Summary
On August 28, 2025, Biophytis S.A. issued a press release. The filing does not contain further details about the content of this press release, only that it was issued.
Why It Matters
This filing indicates Biophytis S.A. has made a public announcement, which could contain material information for investors.
Risk Assessment
Risk Level: low — The filing is a routine announcement of a press release without specific financial or operational details, thus posing minimal immediate risk.
Key Players & Entities
- Biophytis S.A. (company) — Registrant
- August 28, 2025 (date) — Date of press release issuance
- Stanislas Veillet (person) — Contact person
FAQ
What was the subject of the press release issued by Biophytis S.A. on August 28, 2025?
The filing states that Biophytis S.A. issued a press release on August 28, 2025, but does not specify its subject matter.
Is Biophytis S.A. required to file annual reports under Form 20-F or Form 40-F?
The filing indicates that Biophytis S.A. is submitting a Form 6-K, and the checkmark for Form 20-F is not selected, while the checkmark for Form 40-F is also not selected, suggesting it does not file annual reports under either of those specific forms.
What is the principal executive office address for Biophytis S.A.?
The principal executive office address for Biophytis S.A. is Sorbonne University—BC 9, Bâtiment A 4ème étage, 4 place Jussieu, 75005 Paris, France.
What is the Commission File Number for Biophytis S.A.?
The Commission File Number for Biophytis S.A. is 001-38974.
Does Biophytis S.A. have a specific SIC code listed in this filing?
Yes, Biophytis S.A. has a Standard Industrial Classification (SIC) code of 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 244 words · 1 min read · ~1 pages · Grade level 10.2 · Accepted 2025-08-28 10:53:12
Filing Documents
- tm2524633d1_6k.htm (6-K) — 10KB
- tm2524633d1_ex99-1.htm (EX-99.1) — 13KB
- tm2524633d1_ex99-1img001.jpg (GRAPHIC) — 2KB
- 0001104659-25-084446.txt ( ) — 27KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BIOPHYTIS S.A. Date: August 28, 2025 By: /s/Stanislas Veillet Name: Stanislas Veillet Title: Chairman and Chief Executive Officer